Further investigation into the mechanism through which BCR-ABL affects immunity would be required in order to develop a method to target both facets—restoring the “accelerator” (i.e., cDCs) and releasing the “brake” (i.e., monocytes, neutrophils, and basophils) of anti-tumor immunity. Here, ABL1 is linked to neoplasm.